Denosumab is the first gene engineered agent for the treatment of osteoporosis
The incidence of osteoporosis (OP) is growing steadily. Practitioners who long follow up patients with OP frequently ask questions about the duration of treatment with this or that drug particularly in cases of severe OP and at high risk for new fractures when these agents have been used for years a...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Jezik: | Russian |
| Izdano: |
IMA-PRESS LLC
2012-09-01
|
| Serija: | Современная ревматология |
| Teme: | |
| Online dostop: | https://mrj.ima-press.net/mrj/article/view/436 |